Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

555 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?
Abraham AG, Joseph K, Spratlin JL, Zebak S, Alba V, Iafolla M, Ghosh S, Abdelaziz Z, Lui A, Paulson K, Bedard E, Chua N, Tankel K, Koski S, Scarfe A, Severin D, Zhu X, King K, Easaw JC, Mulder KE. Abraham AG, et al. Among authors: chua n. Clin Oncol (R Coll Radiol). 2022 Sep;34(9):e369-e376. doi: 10.1016/j.clon.2022.05.011. Epub 2022 Jun 7. Clin Oncol (R Coll Radiol). 2022. PMID: 35680509 Clinical Trial.
Health care delivery for head-and-neck cancer patients in Alberta: a practice guideline.
Harris JR, Lau H, Surgeoner BV, Chua N, Dobrovolsky W, Dort JC, Kalaydjian E, Nesbitt M, Scrimger RA, Seikaly H, Skarsgard D, Webster MA; Members of the Alberta Provincial Head and Neck Tumour Team. Harris JR, et al. Among authors: chua n. Curr Oncol. 2014 Oct;21(5):e704-14. doi: 10.3747/co.21.1980. Curr Oncol. 2014. PMID: 25302041 Free PMC article.
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Stewart DA, Kuruvilla J, Lee D, Dudebout JJ, Chua N, Larouche JF, Baetz T, Shafey M, Abdel-Samad N, Robinson S, Fleury I, Fraser G, Skrabek P, Kukreti V, Kelly J, Hay AE, Shepherd LE, Chen BE, Crump M. Stewart DA, et al. Among authors: chua n. Br J Haematol. 2024 May 27. doi: 10.1111/bjh.19555. Online ahead of print. Br J Haematol. 2024. PMID: 38802107
Dendrite architecture determines mitochondrial distribution patterns in vivo.
Donovan EJ, Agrawal A, Liberman N, Kalai JI, Adler AJ, Lamper AM, Wang HQ, Chua NJ, Koslover EF, Barnhart EL. Donovan EJ, et al. Among authors: chua nj. Cell Rep. 2024 May 28;43(5):114190. doi: 10.1016/j.celrep.2024.114190. Epub 2024 May 6. Cell Rep. 2024. PMID: 38717903 Free article.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Quantifying the severity of sarcopenia in patients with cancer of the head and neck.
Kubrak C, Martin L, Grossberg AJ, Olson B, Ottery F, Findlay M, Bauer JD, Jha N, Scrimger R, Debenham B, Chua N, Walker J, Baracos V. Kubrak C, et al. Among authors: chua n. Clin Nutr. 2024 Apr;43(4):989-1000. doi: 10.1016/j.clnu.2024.02.020. Epub 2024 Feb 22. Clin Nutr. 2024. PMID: 38484528 Free article.
555 results